2-((4R,7S,10S,13S,16S,19R)-4-((S)-2-(((S)-6-amino-1-((carboxymethyl)amino)-1-oxohexan-2-yl)carbamoyl)pyrrolidine-1-carbonyl)-10-(3-amino-3-oxopropyl)-19-(2-(2-(2-aminoacetamido)acetamido)acetamido)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-7-yl)acetic acid; [8-L-Aspartic acid,12-glycine]terlipressin; [Asp(8), Gly(12)]-Terlipressin [Asp(8)-TLY-COOH]; H-Gly-Gly-Gly-Cys(1)-Tyr-Phe-Gln-Asp-Cys(1)-Pro-Lys-Gly-OH; glycyl-glycyl-glycyl-L-cysteinyl-L-tyrosyl-L-phenylalanyl-L-glutaminyl-L-aspartyl-L-cysteinyl-L-prolyl-L-lysyl-glycine(4->9)-disulfide
Terlipressin EP Impurity L (TFA Salt) is a fully characterized chemical compound used as a reference standard of API Terlipressin. The standard offered is compliant with regulatory guidelines. Terlipressin EP Impurity L (TFA Salt) is used for analytical method development, method validation (AMV), and Quality Controlled (QC) applications during synthesis and formulation stages of drug development and serves as a reference standard for traceability against pharmacopeial standards (USP or EP). Axios Research products are intended for analytical purposes only and are not for human use. CAS - NA
